Test drug XL309 for advanced tumors with HRR gene changes
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can follow study instructions and visits
- Your tumor has progressed on, or you couldn’t tolerate, standard treatment (or there is no suitable standard option)
- Your cancer type and lab results match one of the study groups (many focus on BRCA1/2 or other HRR-related gene changes)
- Your body can handle treatment: blood counts and organ tests are adequate
- You are not currently having major side effects from past treatment (recovery to baseline or mild side effects)
- You can take the study drug by mouth, and you don’t have stomach/intestine problems that would block absorption
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests CX-5461, a new cancer medicine, in people with certain solid tumors that have BRCA1/2 or related “HRD” gene mutations. The goal is to find out how the drug works, what dose is tolerable, and whether it can help shrink tumors.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, ART6043, alone or with another drug called olaparib, for people with advanced or metastatic solid tumors. It may help if your cancer has specific DNA repair problems or if you have breast cancer with a BRCA gene mutation.
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.